News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,699 Results
Type
Article (41589)
Company Profile (231)
Press Release (692867)
Multimedia
Podcasts (98)
Webinars (21)
Section
Business (204973)
Career Advice (2036)
Deals (35641)
Drug Delivery (134)
Drug Development (81633)
Employer Resources (173)
FDA (16555)
Job Trends (15008)
News (347107)
Policy (32766)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2610)
Accelerated approval (55)
ADA (44)
Adcomms (29)
Allergies (192)
Alliances (49599)
ALS (226)
Alzheimer's disease (1843)
Antibody-drug conjugate (ADC) (521)
Approvals (17039)
Artificial intelligence (727)
ASCO (327)
Autoimmune disease (347)
Automation (63)
Bankruptcy (364)
Best Places to Work (11640)
BIO (67)
BIOSECURE Act (20)
Biosimilars (235)
Biotechnology (149)
Bladder cancer (204)
Brain cancer (75)
Breast cancer (803)
Cancer (6324)
Cardiovascular disease (505)
Career advice (1733)
Career pathing (45)
CAR-T (355)
CDC (58)
Celiac Disease (3)
Cell therapy (966)
Cervical cancer (56)
Clinical research (71581)
Collaboration (2209)
Commercialization (1)
Company closure (5)
Compensation (1501)
Complete response letters (85)
COVID-19 (2755)
CRISPR (116)
C-suite (1245)
Cystic fibrosis (157)
Data (8661)
Decentralized trials (3)
Denatured (29)
Depression (175)
Dermatology (98)
Diabetes (667)
Diagnostics (7029)
Digital health (64)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (362)
Drug pricing (203)
Drug shortages (31)
Duchenne muscular dystrophy (307)
Earnings (92235)
Editorial (68)
Employer branding (21)
Employer resources (155)
Events (120644)
Executive appointments (1132)
FDA (20595)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (35)
Funding (1859)
Gene editing (246)
Generative AI (62)
Gene therapy (752)
GLP-1 (1093)
Government (4754)
Grass and pollen (6)
Guidances (421)
Healthcare (19149)
Hematology (192)
HIV (90)
Huntington's disease (62)
IgA nephropathy (113)
Immunology and inflammation (303)
Immuno-oncology (106)
Indications (222)
Infectious disease (3121)
Inflammatory bowel disease (222)
Inflation Reduction Act (14)
Influenza (142)
Intellectual property (320)
Interviews (321)
IPO (16682)
IRA (50)
Job creations (3651)
Job search strategy (1432)
JPM (58)
Kidney cancer (21)
Labor market (112)
Layoffs (576)
Leadership (42)
Legal (7954)
Liver cancer (103)
Longevity (35)
Lung cancer (836)
Lymphoma (477)
Machine learning (65)
Management (61)
Manufacturing (1159)
Marketing (4)
MASH (208)
Medical affairs (1)
Medical device (13998)
Medtech (14171)
Mergers & acquisitions (20279)
Metabolic disorders (1649)
mRNA (230)
Multiple sclerosis (200)
NASH (17)
Neurodegenerative disease (461)
Neuropsychiatric disorders (110)
Neuroscience (3482)
Neurotech (1)
NextGen: Class of 2026 (6530)
Non-profit (4539)
Now hiring (83)
Obesity (758)
Opinion (297)
Ovarian cancer (242)
Pain (266)
Pancreatic cancer (354)
Parkinson's disease (394)
Partnered (36)
Patents (643)
Patient recruitment (772)
Peanut (67)
People (59938)
Pharmaceutical (54)
Pharmacy benefit managers (33)
Phase 1 (22325)
Phase 2 (31539)
Phase 3 (23460)
Pipeline (9889)
Policy (331)
Postmarket research (2569)
Preclinical (9482)
Press Release (64)
Prostate cancer (335)
Psychedelics (57)
Radiopharmaceuticals (345)
Rare diseases (1186)
Real estate (5976)
Recruiting (71)
Regulatory (25856)
Reports (56)
Research institute (2423)
Resumes & cover letters (354)
Rett syndrome (46)
RNA editing (26)
RSV (90)
Schizophrenia (182)
Series A (316)
Series B (233)
Service/supplier (11)
Sickle cell disease (121)
Special edition (25)
Spinal muscular atrophy (169)
Sponsored (48)
Startups (3651)
State (2)
Stomach cancer (18)
Supply chain (134)
Tariffs (87)
The Weekly (67)
Vaccines (1151)
Venture capital (121)
Weight loss (483)
Women's health (138)
Worklife (21)
Date
Today (92)
Last 7 days (496)
Last 30 days (2321)
Last 365 days (30391)
2026 (16367)
2025 (30179)
2024 (35181)
2023 (40081)
2022 (51180)
2021 (55716)
2020 (54087)
2019 (46548)
2018 (35019)
2017 (32111)
2016 (31483)
2015 (37557)
2014 (31328)
2013 (26349)
2012 (28574)
2011 (29270)
2010 (27333)
Location
Africa (743)
Alabama (93)
Alaska (7)
Arizona (367)
Arkansas (14)
Asia (39963)
Australia (6552)
California (14027)
Canada (3973)
China (1496)
Colorado (598)
Connecticut (613)
Delaware (434)
Europe (86520)
Florida (2117)
Georgia (447)
Hawaii (3)
Idaho (63)
Illinois (1154)
India (99)
Indiana (633)
Iowa (25)
Japan (601)
Kansas (135)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1665)
Massachusetts (10053)
Michigan (377)
Minnesota (758)
Mississippi (6)
Missouri (149)
Montana (33)
Nebraska (30)
Nevada (150)
New Hampshire (84)
New Jersey (3673)
New Mexico (30)
New York (3688)
North Carolina (1766)
North Dakota (9)
Northern California (7094)
Ohio (420)
Oklahoma (23)
Oregon (41)
Pennsylvania (2791)
Puerto Rico (31)
Rhode Island (52)
South America (1114)
South Carolina (87)
South Dakota (2)
Southern California (5565)
Tennessee (231)
Texas (2253)
United States (49481)
Utah (417)
Vermont (2)
Virginia (345)
Washington D.C. (81)
Washington State (1115)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
734,699 Results for "avid bioservices inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer
May 11, 2026
·
3 min read
Press Releases
Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy
May 18, 2026
·
2 min read
Neurodegenerative disease
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
June 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Avid Bioservices Appoints Rich McAvoy as Chief Business Officer
January 16, 2026
·
2 min read
Press Releases
Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California
February 24, 2026
·
2 min read
Press Releases
Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer
November 11, 2025
·
2 min read
Press Releases
Avid Bioservices Welcomes Kenneth Bilenberg as new CEO
September 16, 2025
·
3 min read
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
The deal, announced early Sunday afternoon, will see Novartis gain access to Avidity’s neuroscience assets, while the San Diego biotech spins out a new company to shepherd its early-stage precision cardiology programs.
October 26, 2025
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Avidity Played Hardball To Land Favorable Terms in $12B Novartis Deal
At one point in merger negotiations with Novartis, Avidity CEO Sarah Boyce and her team walked, cutting off access to a data room and moving on to a capital raise.
November 25, 2025
·
3 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.
September 11, 2025
·
2 min read
·
Tristan Manalac
1 of 73,470
Next
